Cargando…
Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states
BACKGROUND: Kaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age (classical KS), HIV infection (epidemic KS), or tissue rejection preventat...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470137/ https://www.ncbi.nlm.nih.gov/pubmed/37653396 http://dx.doi.org/10.1186/s40170-023-00316-0 |
_version_ | 1785099619918675968 |
---|---|
author | Privatt, Sara R. Braga, Camila Pereira Johnson, Alicia Lidenge, Salum J. Berry, Luke Ngowi, John R. Ngalamika, Owen Chapple, Andrew G. Mwaiselage, Julius Wood, Charles West, John T. Adamec, Jiri |
author_facet | Privatt, Sara R. Braga, Camila Pereira Johnson, Alicia Lidenge, Salum J. Berry, Luke Ngowi, John R. Ngalamika, Owen Chapple, Andrew G. Mwaiselage, Julius Wood, Charles West, John T. Adamec, Jiri |
author_sort | Privatt, Sara R. |
collection | PubMed |
description | BACKGROUND: Kaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age (classical KS), HIV infection (epidemic KS), or tissue rejection preventatives in transplantation (iatrogenic KS) but can also occur in individuals, predominantly in sub-Saharan Africa (SSA), lacking any obvious immune suppression (endemic KS). The high endemicity of KSHV and human immunodeficiency virus-1 (HIV) co-infection in Africa results in KS being one of the top 5 cancers there. As with most viral cancers, infection with KSHV alone is insufficient to induce tumorigenesis. Indeed, KSHV infection of primary human endothelial cell cultures, even at high levels, is rarely associated with long-term culture, transformation, or growth deregulation, yet infection in vivo is sustained for life. Investigations of immune mediators that distinguish KSHV infection, KSHV/HIV co-infection, and symptomatic KS disease have yet to reveal consistent correlates of protection against or progression to KS. In addition to viral infection, it is plausible that pathogenesis also requires an immunological and metabolic environment permissive to the abnormal endothelial cell growth evident in KS tumors. In this study, we explored whether plasma metabolomes could differentiate asymptomatic KSHV-infected individuals with or without HIV co-infection and symptomatic KS from each other. METHODS: To investigate how metabolic changes may correlate with co-infections and tumorigenesis, plasma samples derived from KSHV seropositive sub-Saharan African subjects in three groups, (A) asymptomatic (lacking neoplastic disease) with KSHV infection only, (B) asymptomatic co-infected with KSHV and HIV, and (C) symptomatic with clinically diagnosed KS, were subjected to analysis of lipid and polar metabolite profiles RESULTS: Polar and nonpolar plasma metabolic differentials were evident in both comparisons. Integration of the metabolic findings with our previously reported KS transcriptomics data suggests dysregulation of amino acid/urea cycle and purine metabolic pathways, in concert with viral infection in KS disease progression. CONCLUSIONS: This study is, to our knowledge, the first to report human plasma metabolic differentials between in vivo KSHV infection and co-infection with HIV, as well as differentials between co-infection and epidemic KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40170-023-00316-0. |
format | Online Article Text |
id | pubmed-10470137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104701372023-09-01 Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states Privatt, Sara R. Braga, Camila Pereira Johnson, Alicia Lidenge, Salum J. Berry, Luke Ngowi, John R. Ngalamika, Owen Chapple, Andrew G. Mwaiselage, Julius Wood, Charles West, John T. Adamec, Jiri Cancer Metab Research BACKGROUND: Kaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age (classical KS), HIV infection (epidemic KS), or tissue rejection preventatives in transplantation (iatrogenic KS) but can also occur in individuals, predominantly in sub-Saharan Africa (SSA), lacking any obvious immune suppression (endemic KS). The high endemicity of KSHV and human immunodeficiency virus-1 (HIV) co-infection in Africa results in KS being one of the top 5 cancers there. As with most viral cancers, infection with KSHV alone is insufficient to induce tumorigenesis. Indeed, KSHV infection of primary human endothelial cell cultures, even at high levels, is rarely associated with long-term culture, transformation, or growth deregulation, yet infection in vivo is sustained for life. Investigations of immune mediators that distinguish KSHV infection, KSHV/HIV co-infection, and symptomatic KS disease have yet to reveal consistent correlates of protection against or progression to KS. In addition to viral infection, it is plausible that pathogenesis also requires an immunological and metabolic environment permissive to the abnormal endothelial cell growth evident in KS tumors. In this study, we explored whether plasma metabolomes could differentiate asymptomatic KSHV-infected individuals with or without HIV co-infection and symptomatic KS from each other. METHODS: To investigate how metabolic changes may correlate with co-infections and tumorigenesis, plasma samples derived from KSHV seropositive sub-Saharan African subjects in three groups, (A) asymptomatic (lacking neoplastic disease) with KSHV infection only, (B) asymptomatic co-infected with KSHV and HIV, and (C) symptomatic with clinically diagnosed KS, were subjected to analysis of lipid and polar metabolite profiles RESULTS: Polar and nonpolar plasma metabolic differentials were evident in both comparisons. Integration of the metabolic findings with our previously reported KS transcriptomics data suggests dysregulation of amino acid/urea cycle and purine metabolic pathways, in concert with viral infection in KS disease progression. CONCLUSIONS: This study is, to our knowledge, the first to report human plasma metabolic differentials between in vivo KSHV infection and co-infection with HIV, as well as differentials between co-infection and epidemic KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40170-023-00316-0. BioMed Central 2023-08-31 /pmc/articles/PMC10470137/ /pubmed/37653396 http://dx.doi.org/10.1186/s40170-023-00316-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Privatt, Sara R. Braga, Camila Pereira Johnson, Alicia Lidenge, Salum J. Berry, Luke Ngowi, John R. Ngalamika, Owen Chapple, Andrew G. Mwaiselage, Julius Wood, Charles West, John T. Adamec, Jiri Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states |
title | Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states |
title_full | Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states |
title_fullStr | Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states |
title_full_unstemmed | Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states |
title_short | Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states |
title_sort | comparative polar and lipid plasma metabolomics differentiate kshv infection and disease states |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470137/ https://www.ncbi.nlm.nih.gov/pubmed/37653396 http://dx.doi.org/10.1186/s40170-023-00316-0 |
work_keys_str_mv | AT privattsarar comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT bragacamilapereira comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT johnsonalicia comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT lidengesalumj comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT berryluke comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT ngowijohnr comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT ngalamikaowen comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT chappleandrewg comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT mwaiselagejulius comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT woodcharles comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT westjohnt comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates AT adamecjiri comparativepolarandlipidplasmametabolomicsdifferentiatekshvinfectionanddiseasestates |